Get the Stockscreener App
16.38
3.59%
-0.61
Sionna Therapeutics Inc stock is traded at $16.38, with a volume of 101.01K.
It is down -3.59% in the last 24 hours and up +27.72% over the past month.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
See More
Previous Close:
$16.99
Open:
$16.65
24h Volume:
101.01K
Relative Volume:
0.62
Market Cap:
$759.27M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.88%
1M Performance:
+27.72%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.22
$17.15
1-Week Range:
$15.99
$18.85
52-Week Range:
$7.255
$24.90
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
617-819-2020
Address
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
16.38 | 759.27M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Initiated | Guggenheim | Buy |
| Mar-04-25 | Initiated | Stifel | Buy |
| Mar-04-25 | Initiated | TD Cowen | Buy |
Sionna Therapeutics Inc Stock (SION) Latest News
Sionna Therapeutics reports annual meeting results By Investing.com - Investing.com South Africa
Sionna Therapeutics Holds Annual Stockholders Meeting - TipRanks
Sionna Therapeutics reports annual meeting results - Investing.com
Sionna's experimental CFTR modulators show promise in preclinical tests - Cystic Fibrosis News Today
Odyssey Therapeutics pulls plug on IPO plans - The Business Journals
Odyssey Ends Quest for Nasdaq, Pulls IPO Application After Nearly 5 Months - BioSpace
Odyssey pulls back from IPO plans as public markets remain frozen - Endpoints News
Sionna Therapeutics advances CF treatment with new data By Investing.com - Investing.com South Africa
Sionna Therapeutics advances CF treatment with new data - Investing.com India
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model - GlobeNewswire
NBD1 stabilizers safe in healthy volunteers, Sionna says - Cystic Fibrosis News Today
Petri Dish: PepGen halts work on Duchenne drug; Needham biotech announces layoffs - The Business Journals
2 Soaring Stocks Wth More Upside Potential - AOL.com
Transcript : Sionna Therapeutics, Inc.Special Call - marketscreener.com
Sionna advances cystic fibrosis treatments to new trials By Investing.com - Investing.com South Africa
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial - Benzinga
Stifel analysts reiterate buy rating on Sionna Therapeutics stock By Investing.com - Investing.com Canada
Sionna Therapeutics Announces Positive Phase 1 Results For SION-719, SION-451 In Cystic Fibrosis - Nasdaq
Sionna advances cystic fibrosis treatments to new trials - Investing.com Australia
Sionna Therapeutics Reports Positive Phase 1 Trial Results - TipRanks
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis - The Manila Times
Sionna Therapeutics Announces Positive Phase 1 Data For Nbd1 Stabilizers Sion-719 And Sion-451 And Advances Both Programs In Clinical Development For Cystic Fibrosis - marketscreener.com
Sionna Therapeutics Announces Positive Phase 1 Data for - GlobeNewswire
Sionna selects which cystic fibrosis drug it will study in a mid-stage test - Endpoints News
Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
3 No-Brainer Healthcare Stocks to Buy in June - AOL.com
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 6% – Here’s What Happened - Defense World
Why Summit Therapeutics Plunged Today - AOL.com
3 High-Flying Stocks That Could Soar Even More - AOL.com
Sionna Therapeutics to Present Preclinical Data on CFTR Modulators at European Cystic Fibrosis Conference - Nasdaq
Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference - GlobeNewswire
Sionna Therapeutics (NASDAQ:SION) Shares Gap Down Following Weak Earnings - Defense World
Sionna Therapeutics Phase 1 Topline Data For Nbd1 Stabilizers Sion-719 & Sion-451 Expected This Quarter - marketscreener.com
Sionna Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
Private equity firms invested in Sionna Therapeutics, Inc. (NASDAQ:SION) copped the brunt of last week's US$56m market cap decline - simplywall.st
While individual investors own 26% of Sionna Therapeutics, Inc. (NASDAQ:SION), private equity firms are its largest shareholders with 56% ownership - Yahoo Finance
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip - AOL.com
Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025 - The Manila Times
Revolutionary Cystic Fibrosis Treatment Developer Sionna Takes Stage at Major Healthcare Conference - Stock Titan
2 Beaten-Down Stocks With Incredible Upside Potential - AOL.com
OrbiMed-backed biotech looks to challenge Vertex in cystic fibrosis by 'drugging the undruggable' - Endpoints News
Alcoa Posts Weak Revenue, Joins QXO And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com
In 2025, biotech IPOs were supposed to bounce back. It hasn't happened yet. - The Business Journals
Sionna Therapeutics (NASDAQ:SION) Trading Down 4.2%What's Next? - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Reaches New 1-Year Low on Disappointing Earnings - Defense World
Stifel maintains Buy rating on Sionna Therapeutics stock at $32 target - Investing.com Australia
SEC Form 10-K filed by Sionna Therapeutics Inc. - Quantisnow
Form 10-K Sionna Therapeutics, For: Dec 31 - StreetInsider
Sionna Therapeutics Inc Stock (SION) Financials Data
There is no financial data for Sionna Therapeutics Inc (SION). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):